Skip to content

Jeffrey Trocio

  • Global Health & Value - Outcomes & Evidence
  • Pfizer Inc
  • 11h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 624CitationsNumber of citations received by Jeffrey's publications. Updated daily.

Other IDs

Research interests

observationalpatient reported outcomesproanticoagulationcardiovascularceroabnoacatrial fibrillationhiv

Co-authors (157)

Publications (5)

  • Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United States

    • Deitelzweig S
    • Evans M
    • Trocio J
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting

    • Henk H
    • Cao F
    • Tuell K
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Effect of apixaban versus warfarin use on health care resource utilization and costs among elderly patients with nonvalvular atrial fibrillation

    • Deitelzweig S
    • Luo X
    • Gupta K
    • et al.
    N/AReaders
    1Citations
    Get full text
  • Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan

    • Amin A
    • Keshishian A
    • Vo L
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Leveraging real-world evidence in disease-management decision-making with a total cost of care estimator

    • Nguyen T
    • Trocio J
    • Kowal S
    • et al.
    N/AReaders
    2Citations

Professional experience

Global Health & Value - Outcomes & Evidence

Pfizer Inc.

October 2006 - Present